... received second-line immunotherapy after disease progression. The relationship between the expression level of SIRT7 by immunohistochemistry and clinicopathological characteristics, disease-free survival (DFS), overall survival (OS), and OS after progression (POS) was analyzed. Results: Over a mean follow...

... or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 Adjuvant therapy Immunotherapy Renal cell carcinoma Real-world data For localized and locally advanced renal cell carcinoma (RCC), partial or radical nephrectomy...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 Testicular cancer Immune checkpoint inhibitor KRAS mutation Immunotherapy Chemotherapy Testicular germ cell tumors (TGCTs...

... closely associated with tumor immunotherapy and prognosis. The complex composition of the urological tumor microenvironment not only varies greatly in response to immunotherapy, but the prognostic value of TLSs in different urological tumors remains controversial. Summary: We searched PubMed, Web...

...) in metastatic urothelial carcinoma undergoing immunotherapy are sparse. Consequently, we performed a prospective clinical pilot study about HRQoL using the Functional Assessment of Cancer Therapy – Immune Checkpoint Modulator (FACT-ICM) questionnaire. Materials and Methods: Formally, this study is a prospective...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Checkpoint inhibition First-line therapy Immunotherapy Metastatic renal-cell carcinoma First-line treatment...

... to in the content or advertisements. Genitourinary tract infection Immunotherapy Sublingual administration Urinary tract infections (UTIs) are principally defined as the existence of bacteria in the urinary tract capable of producing functional and/or morphological disorders. Significant bacteriuria...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Urinary bladder neoplasms Immunotherapy Interleukin-2  Instillation Marker tumour The initial management of non-muscle-invasive bladder...

... of Urology (EAU) and the National Comprehensive Cancer Network (NCCN) guidelines as the elective intravesical adjuvant regimen in intermediate- and high-risk NMIBC, which is conservatively treated [ 4, 6 ]. Non-muscle invasive bladder cancer Intravesical instillation Immunotherapy Compliance...

...Chong Xie; Guomin Wang Introduction: Gene-modified cell vaccines are now considered to be the best way to achieve immunotherapy for a variety of cancers including prostate cancer (PCa). XAGE-1b is a member of the cancer/testis antigen family which has demonstrated strong immunogenicity. We...

... at 1, 3 and 5 years in patients with non-muscle-invasive bladder cancer (NMIBC) who underwent a transurethral resection of bladder cancer following intravesical adjuvant chemotherapy or immunotherapy if indicated and to compare them with the European Organization for Research and Treatment of Cancer...

... with anti-Fas monoclonal antibody. These results suggest that selective COX-2 inhibitors in combination with immunotherapy may be useful in treating patients with RCC. 14 07 2008 15 03 2009 13 4 2010 © 2010 S. Karger AG, Basel 2010 Copyright / Drug Dosage / Disclaimer Copyright...

...S. Kleinknecht; K.-H. Bichler; W.L. Strohmaier Assessing the peripheral blood immune status, we had found evidence of immunosuppression in metastatic renal cell carcinoma. Since immunosuppression might interfere with the outcome of immunotherapy, it was submitted to further investigation...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Bladder carcinoma Superficial Recurrent Immunotherapy Bacillus Calmette-Guérin Intradermal Intravesical Original...

.... Superficial bladder cancer Immunotherapy Intravesical therapy Bacillus Calmette-Guérin Epirubicin Original Paper Urol Int 1994;52:69-72 AliErol Suat Ozgiir Murat Basgr Selahattin Qetin Department of Urology, Advanced Specialization Hospital of Turkey, Ankara, Turkey Trial with Bacillus Calmette-Guerin...

... subjective improvement for 2 months. However, during the 3rd month of treatment there was global deterioration which progressed further till his demise during the 4th month. The beneficial role, if any, of combined hormonal and immunotherapy in advanced prostatic carcinoma is discussed as also the natural...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Superficial bladder cancer Toxicity Immunotherapy Bacillus Calmette-Guérin Intravesical therapy Clinical use Original Papers Urol Int 1990;45...

...T. Schärfe; S. Müller; H. Riedmiller; G.H. Jacobi; R. Hohenfellner 119 patients with stage-IV renal cell carcinoma were treated using immunotherapy with autologous tumor vaccine. The immunization was carried out at monthly intervals, the patients were restaged every 3 months using X-ray, ultrasound...

... and human urogenital cancers were also identified by the PAP study. Then, local immunotherapy with OK-432 was carried out in 38 patients with superficial bladder tumor and the tumors were eliminated in 23.7%. In 77.8% of the complete response and in 10.3% of the no change, the tumor tissues demonstrated...

... in 10 (21.7%) patients at the end of the BCG cycles. Radical cystectomy was done in 10 patients. The tumor-free survival rate of all patients including those who underwent cystectomy is 84.8% (39 of 46) with a median follow-up of 61 (range 39–118) months. Conclusion: Adjuvant immunotherapy with BCG...